Literature DB >> 27379855

[Drug Treatment of Chronic Venous Diesease].

Miloš D Pavlović1.   

Abstract

Chronic venous disease (CVD) affects at least 15-25 % of the general population incurring not only high morbidity but also considerable economical burden. The mainstay of modern treatment of CVD are endovenous therapeutic procedures and compression therapy. As far as the pathogenesis of CVD is being gradually unraveled the interest in drugs able to impact the process is growing. Here we have presented an overview of a majority of oral preparations used so far to treat CVD including venous leg ulcers. After several decades of clinical use a few flavonoid preparations, in the first place micronized purified flavonoid fraction, collected enough evidence to recommend them as a short-term adjunct treatment of CVD. However, other compounds are also promising in this regards. Yet, we need more larger and longer-term clinical trials to more precisely define effects, cost-effectiveness and, above all, capacity for prophylactic application of the drugs. Learning more about basis of CVD will help design new drugs directed at specific aspects of the disease process.

Entities:  

Keywords:  Benzopyrones; Calcium dobesilate; Chronic venous disease; Drugs; Flavonoids; Oral treatment; Varicose veins

Mesh:

Substances:

Year:  2016        PMID: 27379855     DOI: 10.1007/s10354-016-0480-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  60 in total

1.  Synthesis and anti-angiogenesis activity of coumarin derivatives.

Authors:  Seokjoon Lee; Krishnamoorthy Sivakumar; Woon-Seob Shin; Fang Xie; Qian Wang
Journal:  Bioorg Med Chem Lett       Date:  2006-06-21       Impact factor: 2.823

Review 2.  Pathogenesis of primary varicose veins.

Authors:  C S Lim; A H Davies
Journal:  Br J Surg       Date:  2009-11       Impact factor: 6.939

3.  Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial.

Authors:  D Janssens; C Michiels; G Guillaume; B Cuisinier; Y Louagie; J Remacle
Journal:  J Cardiovasc Pharmacol       Date:  1999-01       Impact factor: 3.105

Review 4.  Dutch Venous Ulcer guideline update.

Authors:  M Birgitte Maessen-Visch; Kees-Peter de Roos
Journal:  Phlebology       Date:  2014-05-19       Impact factor: 1.740

Review 5.  Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.

Authors:  Nicholas Farinola; Neil Piller
Journal:  Lymphat Res Biol       Date:  2005       Impact factor: 2.589

6.  Effect of Ginkor Fort on hypoxia-induced neutrophil adherence to human saphenous vein endothelium.

Authors:  T Arnould; C Michiels; D Janssens; N Berna; J Remacle
Journal:  J Cardiovasc Pharmacol       Date:  1998-03       Impact factor: 3.105

7.  Lipid peroxidation and lysosomal integrity in different inflammatory models in rats: the effects of indomethacin and naftazone.

Authors:  A M Agha; M Z Gad
Journal:  Pharmacol Res       Date:  1995-11       Impact factor: 7.658

8.  Effects of Centella asiatica extract on mucopolysaccharide metabolism in subjects with varicose veins.

Authors:  M R Arpaia; R Ferrone; M Amitrano; C Nappo; G Leonardo; R del Guercio
Journal:  Int J Clin Pharmacol Res       Date:  1990

Review 9.  Calcium dobesilate: pharmacology and future approaches.

Authors:  T Tejerina; E Ruiz
Journal:  Gen Pharmacol       Date:  1998-09

10.  Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial.

Authors:  Sergio Q Belczak; Igor R Sincos; Walter Campos; Julio Beserra; Gilberto Nering; Ricardo Aun
Journal:  Phlebology       Date:  2013-05-16       Impact factor: 1.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.